
Pharmaceutical firm Lilly’s orforglipron was associated with greater reductions in body weight and blood glucose than oral semaglutide in adults …

The first 90 days after starting antipsychotic treatment are a critical period for monitoring blood glucose and weight, according to …

Boehringer Ingelheim’s investigational survodutide produced weight loss of up to 13.1% after 76 weeks in people with obesity or overweight …

Researchers at Northumbria University are leading a £1.3m study aimed at helping GP practices improve care for young adults living …

MetP Pharma has released new data highlighting the advantages of its MetP technology in delivering neuroactive peptides, particularly semaglutide, directly …

Effective from September 2025, AOTI’s Topical Wound Oxygen (TWO2) therapy has been awarded inclusion in the NHS supply chain. It …

Recce Pharmaceuticals have announced positive patient data from its phase 2 clinical trial into RECCE 327 (R327), for the treatment …

Roche has announced that it has received the CE Mark for its Accu-Chek SmartGuide continuous glucose monitoring (CGM) solution.

Vertex Pharmaceuticals has announced new data from its phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated …

Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended …

Roche has shared the latest data on its novel solution for continuous glucose monitoring (CGM), including a CGM sensor and …

Novo Nordisk has shared topline results from the COMBINE 3 phase 3a trial of once-weeklly IcoSema, a fixed-ration combination treatment …

Eli Lilly has announced its new digital healthcare experience, LillyDirect, which will benefit patients in the US with obesity, migraine …

Roche has announced that it has entered into a definitive merger agreement with Carmot Therapeutics, in which it will acquire …

Abbott and Bigfoot Biomedical have announced a definitive agreement for Abbott to acquire Bigfoot, however this transaction is still subject …